Selective vitamin D receptor modulators and their effects on colorectal tumor growth

Journal of Steroid Biochemistry and Molecular Biology

Volumn 103, Issue 3-5, 2007, Pages 757-762

  Spina, C S ^a   Ton, L ^a   Yao, M ^b   Maehr, H ^c   Wolfe, M M ^b   Uskokovic, M ^c   Adorini, L ^c   Holick, M F ^a  

^a Vitamin D   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Bioxell Inc   (United States)

Author keywords

Anti tumor; Colorectal cancer; MC 26; MMP 9 and MMP 2; Vitamin D; Vitamin D analogue

Indexed keywords

CALCITRIOL; MATRIX METALLOPROTEINASE; PROTEINASE; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM BLOOD LEVEL; CANCER INHIBITION; CANCER INVASION; CANCER THERAPY; CELL PROLIFERATION; COLORECTAL TUMOR; CONTROLLED STUDY; DRUG MECHANISM; MALE; METASTASIS; MOUSE; NONHUMAN; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CALCITRIOL; CALCIUM; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; MALE; MICE; MICE, INBRED BALB C; MUSCLE NEOPLASMS; NEOPLASM INVASIVENESS; RECEPTORS, CALCITRIOL;

EID: 33947216633     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2006.12.040     Document Type: Article

References (36)

1. American Cancer Society, 2006.
2. DevCan: Probability of Developing or Dying of Cancer Software, Version 6.0 Statistical Research and Applications Branch, NCI, 2005. http://srab.cancer.gov/devcan.
3. Lubbe W.J., Zhou Z.Y., Fu W., Zuzga D., Schultz S., Fridman F., Muschel R.J., Waldman S.A., and Pitari G.M. Tumor epithelial cell matrix metalloproteinase 9 is a target for anti-metastatic therapy in colorectal cancer. Clin. Cancer Res. 12 6 (2006) 1876-1882
4. Liang H., Wang X.N., Wang B.G., Pan Y., Liu N., Wang D.C., and Hao X.S. Prognostic factors of young patients with colon cancer after surgery. World J. Gastroenterol. 12 9 (2006) 1458-1462
5. Liotta L.A. Tumor invasion and metastases-role of the extracellular matrix: Rhoads memorial award lecture. Cancer Res. 46 (1986) 1-7
6. Babai F. Edute ultrastuctural sur la pathogénie de l'invasion du muscle strie par des tumeurs transplantable. J. Ultrastruct. Res. 56 (1976) 287-297
7. Stetler-Stevenson W.G., Hewitt R., and Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin. Cancer Biol. 7 (1996) 147-154
8. 3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis 27 1 (2006) 32-42
9. Holst-Hansen C., Johannessen B., Hoyer-Hansen G., Romer J., Ellis V., and Brunner N. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin. Exp. Metastasis 14 (1996) 297-307
10. Grondahl-Hansen J., Christensen I.J., Rosenquist C., Brunner N., Mouridsen H.T., Dano K., and Bilchert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinoma are associated with poor prognosis. Cancer Res. 53 (1993) 2513-2521
11. Yao M., Lam E.C., Kelly C.R., Zhou W., and Wolfe M.M. Cycloxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br. J. Cancer 45 (2004) 311-317
12. Emmert-Buck M.R., Roth J.M., Zhuan Z., Campo E., Rozhin J., Slone B.F., Liotta L.A., and Stetler-Stevenson W.G. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am. J. Pathol. 145 (1994) 1285-1290
13. Kim H.S., Kim M.H., Jeong M., Hwang Y.S., Lim S.H., Shin B.A., Ahn B.W., and Jung Y.D. EGCG blocks tumor promoter-induced MMP-9 expression via suppression of MAPK and AP-1 activation in human gastric AGS cells. Anticancer Res. 24 (2004) 747-753
14. Bernhard E.J., Gruber S.B., and Muschel R.J. Direct evidence linking expression of matrix metalloproteinase 9 to the metastatic phenotype in transformed rat embryo cells. PNAS 91 (1994) 4293-4297
15. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of metalloproteinase-1 (TIMP1) in B16F10 melanoma cells. J. Natl. Cancer Inst. 84 (1992) 1017-1022
16. W.B. Grant, Epidemiology of disease risks in relation to vitamin D insufficiency. Progr. Biophys. Mol. Biol. (Epub early).
17. Grant W.B., Garland C.F., and Holick M.F. Comparisons of estimated economic burdens due to insufficient solar ultraviolet irradiance and vitamin D and excess solar UV irradiance for the United States. Photochem. Photobiol. 81 (2005) 1276-1286
18. Osborne J.E., and Hutchinson P.E. Vitamin D and systemic cancer: is this relevant to malignant melanoma?. Br. J. Dermatol. 147 (2002) 197-213
19. 3 in human colon cancer cells. Cancer Res. 63 (2003) 7799-7806
20. Beer T.M., and Myrthue A. Calcitriol in cancer treatment: from the lab to the clinic. Mol. Cancer Ther. 3 3 (2004) 373-381
21. Sung V., and Feldman D. 1,25-Dihydroxyvitamin D3 decreases human prostate cancer and cell adhesion and migration. Mol. Cell Endocrinol. 164 (2000) 133-143
22. 3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ. 11 (2000) 221-229
23. Schwartz G.G., Wang M.H., Zang M., Singh R.K., and Siegal G.P. 1a,25-Dihydroxivitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol. Biomarkers Prev. 6 (1997) 727-7132
24. Getzenberg R.H., Light B.W., Lapco P.E., Konety B.R., Nangia A.K., Acierno J.S., Dhir R., Shurin Z., Day R.S., Trump D.L., and Johnson C.S. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 50 6 (1997) 999-1006
25. Koeffler H.P., Hirji K., and Itri L. 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human pre-leukemic and leukemic cells. Cancer Treat. Rep. 69 12 (1985) 1399-1407
26. Gross C., Stamey T., Hancock S., and Feldman D. Treatment of early recurrent prostate cancer with 1, 25-dihydroxyvitamin D3 (calcitriol). J. Urol. 159 6 (1998) 2035-2039
27. Spina C., Tangpricha V., Yao M., Zhou W., Wolfe M.M., Maehr H., Uskokovic M., Adorini L., and Holick M.F. Colon cancer and solar ultraviolet B radiation and prevention and treatment of colon cancer in mice with vitamin D and its Gemini analogs. JSBMB 97 (2005) 111-120
28. Chen T.C., and Holick M.F. Hexafluoro-1,25-dihydroxyvitamin D3 has markedly increased potency in inhibiting proliferation of cultured human keratinocytes compared with 1, 25-dihydroxyvitamin D3. Br. J. Dermatol. 143 (2000) 72-78
29. Griswald D.P., and Corbett T.H. A colon tumor model for anticancer agent evaluation. Cancer 36 (1975) 2441-2444
30. Yao M., Lam E.C., Kelly C.R., Zhou W., and Wolfe M.M. Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br. J. Cancer 90 3 (2004) 712-719
31. Bouillon R., Okamura W.H., and Norman A.W. Structure-function relationships in the vitamin D endocrine system. Endocr. Rev. 16 (1995) 200-257
32. Holick M.F. Vitamin D: a millennium perspective. J. Cell Biochem. 88 (2003) 296-307
33. Carlberg C. Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Rec. Res. Cancer Res. 164 (2003) 29-42
34. Issa L.L., Leong G.M., and Eisman J.A. Molecular mechanisms of vitamin D receptor action. Inflamm. Res. 47 (1998) 451-475
35. 3 inducible transcription factor and its role in the vitamin D action. Endocr. Reg. 38 (2004) 29-38
36. A.C. Berger, E.R. Sigurdson, T. LeVoyer, A. Hanlon, R.J. Mayer, J.S. Macdonald, P.J. Catalano, D.G. Haller, Colon cancer survival is associated with decreasing ration of metastatic to examined lymph nodes, 23 (34) (2005) 8706-8712.